Unibest 优贝德

APIs Recommended for You

Three inputs drive the ranking: the region of your target market, the indication classes you follow, and each molecule's patent-expiry window. Every card states why it was picked.

What drives these picks

Region
北美

合规与文件成本最高,但单价与订单体量最大

Indications you follow
Urology / Women's Health
Visitor region (by IP)
USip

ANDA 路线;原料端需 DMF 并在 ANDA 中引用,US GMP 与场地登记是硬条件

No direction yet? This page picks from our catalogue. To answer what a market will need next, use the demand-chain board and work down from economy, demography and diet.

Demand-chain board →

Which therapeutic areas do you follow?

Multi-select, change any time

Sign in and we remember your market and interests — you land straight on this page next time.

Urology / Women's HealthTo be assessed9 intermediates
Elinzanetant

Non-hormonal treatment of menopausal vasomotor symptoms (hot flashes)

Why it was picked
  • · 你关注的适应症:泌尿 / 女性健康(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
Urology / Women's HealthTo be assessed6 intermediates
Fezolinetant

Moderate-to-severe vasomotor symptoms (hot flashes) of menopause

Why it was picked
  • · 你关注的适应症:泌尿 / 女性健康(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
Cardiovascular / RenalOff-patent · 1995
Methyldopa hydrate

Treatment of hypertension, especially pregnancy-induced hypertension

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(+25)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyOff-patent · 2026 (indicative)
Ruxolitinib

Myelofibrosis and polycythemia vera; topical formulations for vitiligo and atopic dermatitis

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(+25)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Cardiovascular / RenalExpiring within 2 yrs · 2027 (indicative)
Edoxaban

Stroke prevention in non-valvular atrial fibrillation; treatment of DVT and pulmonary embolism

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 2 年内到期(+20)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed3 intermediates
Apalutamide

Non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
Cardiovascular / RenalTo be assessed6 intermediates
Finerenone

Chronic kidney disease (CKD) associated with type 2 diabetes; slows renal function decline and cardiovascular events

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
CNS / PsychiatryOff-patent · 2020 (to verify)
Eliprodil

Exploratory indications: neuropathic pain, post-stroke neuroprotection

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(待核实)(+10)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
CNS / PsychiatryOff-patent · 2020 (to verify)
Elzasonan

Depressive and anxiety disorders

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(待核实)(+10)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
CNS / PsychiatryOff-patent · 2020 (to verify)
Emapunil

Anxiety and other mood disorders

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(待核实)(+10)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
CNS / PsychiatryOff-patent · 2020 (to verify)
Vipadenant

Parkinson's disease; also reverses adenosine-pathway tumor immune evasion

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(待核实)(+10)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed
Afuresertib

Targeted therapy of multiple myeloma and various solid tumors

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)

Patent expiry compiled from public sources and indicative only; defer to national patent offices and the Orange Book.